, Volume 118, Issue 2, pp 183–187 | Cite as

Moclobemide versus fluoxetine for a major depressive episode

  • C. Reynaert
  • P. Janne
  • M. Parent
  • J. Mirel
  • L. Hazzen
Original Investigation


The efficacy and tolerability of moclobemide (300–600 mg daily) and fluoxetine (20–40 mg daily) were compared in a 6-week, double-blind study of 65 inpatients and 34 outpatients suffering from major depressive episodes (DSM III-R). No statistically significant differences between the two treatment groups were noted regarding efficacy (HDRS, CGI) or safety (adverse events, laboratory examination, vital signs). Moclobemide (300–600 mg daily) and fluoxetine (20–40 mg daily) would thus appear to be comparable both in antidepressant efficacy and tolerability. Doubling the low dosage in non-responders after 3 weeks resulted in a statistically significant improvement of CGI in the moclobemide group by comparison with the fluoxetine group at study end, suggesting that 600 mg moclobemide/day can still improve the patient's condition, while 40 mg fluoxetine/day does not. Sexual dysfunction was reported in two patients taking fluoxetine.

Key words

Moclobemide Fluoxetine Major depressive episode Antidepressant drug Dosage Sexual dysfunction 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amrein R, Güntert TW, Dingemanse J, Lorscheid T, Stabl M, Schmid-Burgk (1992) Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology 106:S24-S31Google Scholar
  2. Baier D, Philipp M (1994) Effects of antidepressants on sexual function. Fortschr Neurol Psychiatr 62:14–20Google Scholar
  3. Bakish D, Bradwejn J, Nair N, McClure J, Remick R, Bulger L (1992) A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study. Psychopharma-cology 106:S98-S101Google Scholar
  4. Balon R, Vikram K, Yeragani V, Pohl R, Ramesh C (1993) Sexual dysfunction during antidepressant treatment. J Clin Psychiatry 54:209–212Google Scholar
  5. Baumhackl U, Bizière K, Fischbach R (1989) Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM III): an Austrian double-blind, multicentre study. Br J Psychiatry 155, [suppl. 6]:78–83Google Scholar
  6. Burkard WP, Bonetti EP, Da Prada M, Martin JR, Polc P, Schaffner R, Scherschlicht R, Hefti F, Müller RKM, Wyss PC, Haefely W (1989) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248:391–399Google Scholar
  7. Chen DT, Ruch R (1993) Safety of moclobemide in clinical use. Clin Neuropharmacol 16[suppl. 2]:S63-S68Google Scholar
  8. Geerts S, Bruynooghe F, De Cuyper H, Demeulemeester F, Haazen L (1994) Clin Neuropharmacol 17[suppl. 1]:S50-S57Google Scholar
  9. Guelfi JD, Payan C, Fermanian J, Pedarriosse A-M, Manfredi R (1992) Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial. Br J Psychiatry 160:519–524Google Scholar
  10. Louie AK, Lewis TB, Lannon RA (1993) Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 54:435–438Google Scholar
  11. Montgomery SA (1989) The efficacy of fluoxetine as an antidepressant in the short and long term. Int Clin Psychopharmacol 4[suppl. 1]:113–119Google Scholar
  12. Pande AC, Sayler ME (1993) Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol 8:267–269Google Scholar
  13. Patterson WM (1993) Fluoxetine-induced sexual dysfunction (letter). J Clin Psychiatry 54:71Google Scholar
  14. Philipp M, Kohnen R, Benkert O (1993) A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction. Int Clin Psychopharmacol 7:149–153Google Scholar
  15. Silverstone T (1993) Moclobemide—placebo-controlled trals. Int Clin Psychopharmacol 7:133–136Google Scholar
  16. Versiani M, Oggero U, Alterwain R, Capponi R, Dajas F, Heinze-Martin G, Marquez CA, Poleo MA, Rivero-Alzmanor LE, Rossel L, Schmid-Burgk W, Ucha Udabe R (1989) A double-blind comparative trial of moclobemide versus imipramine and placebo in major depressive episodes. Br J Psychiatry 155[suppl. 6]:72–77Google Scholar
  17. Versiani M, Nardi AE, Figueira ILV, Stabl M (1990) Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo. Acta Psychiatr Scand Suppl. 360:24–28Google Scholar
  18. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M (1988) Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 24 [1]:183–188Google Scholar
  19. Wernicke JF, Janet C, Bosomworth, Ashbrook E (1989) Fluoxetine at 20 mg per day: the recommended and therapeutic dose in the treatment of depression. Int Clin Psychopharmacol 4 [suppl. 1]:63–67Google Scholar
  20. Williams R, Edwards RA, Newburn GM, Mullen R, Menkes DB, Segkar C (1993) A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. Int Clin Psychopharmacol 7:155–158Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • C. Reynaert
    • 1
  • P. Janne
    • 1
  • M. Parent
    • 2
  • J. Mirel
    • 3
  • L. Hazzen
    • 4
  1. 1.University Department of PsychiatryClinical University of Mont-GodinneMont (Yvoir)Belgium
  2. 2.Psychiatric HospitalHenri-ChapelleBelgium
  3. 3.Psychogeriatric HospitalMontignyBelgium
  4. 4.N.V. Roche S.A.BrusselsBelgium

Personalised recommendations